In medicine, Raynaud's phenomenon/reɪˈnoʊz/ or Raynaud phenomenon is excessively reduced blood flow in response to cold or emotional stress, causing discoloration of the fingers, toes, and occasionally other areas. This condition may also cause nails to become brittle with longitudinal ridges. Named after French physician Maurice Raynaud (1834–1881), the phenomenon is believed to be the result of vasospasms that decrease blood supply to the respective regions.
Raynaud's phenomenon by itself is just a sign (hypoperfusion) accompanied by a symptom (discomfort). When linked to pathogenesis, it can be part of Raynaud's disease (also known as primary Raynaud's phenomenon), where the cause is unknown, or part of Raynaud's syndrome (secondary Raynaud's phenomenon), which is a syndrome caused by a known primary disease, most commonly connective tissue disorders such as systemic lupus erythematosus. Measurement of hand-temperature gradients is one tool used to distinguish between the primary and secondary forms.
The condition can cause pain within the affected extremities, discoloration (paleness), and sensations of cold and/or numbness. This can often be distressing to those who are not diagnosed, and sometimes it can be obstructive. If someone with Raynaud's is placed in too cold a climate, it could potentially become dangerous.
An image taken by a thermographic camera. The top hand belongs to a person who suffers from Reynaud's, the bottom hand does not. Red indicates a heat signature whilst green indicates little/no heat.
When exposed to cold temperatures, the blood supply to the fingers or toes, and in some cases the nose or earlobes, is markedly reduced; the skin turns pale or white (called pallor), and becomes cold and numb.
When the oxygen supply is depleted, the skin color turns blue (called cyanosis).
These events are episodic, and when the episode subsides or the area is warmed, the blood flow returns and the skin color first turns red (rubor), and then back to normal, often accompanied by swelling, tingling, and a painful "pins and needles" sensation.
All three color changes are observed in classic Raynaud's. However, not all patients see all of the aforementioned color changes in all episodes, especially in milder cases of the condition. Symptoms are thought to be due to reactive hyperemias of the areas deprived of blood flow.
In pregnancy, this sign normally disappears owing to increased surface blood flow. Raynaud's also has occurred in breastfeeding mothers, causing nipples to turn white and become extremely painful.Nifedipine, a calcium channel blocker and vasodilator, was recommended to increase blood flow to the extremities and noticeably relieved pain to the breast in an extremely small study group.
It is important to distinguish Raynaud's disease from syndrome. In order to diagnose these two forms of Raynaud's, a doctor may look for signs of arthritis or vasculitis and may conduct a number of laboratory tests.
Primary Raynaud's (disease)
Raynaud's disease, or "Primary Raynaud's", is diagnosed if the symptoms are idiopathic, that is, if they occur by themselves and not in association with other diseases. Some refer to Primary Raynaud's disease as "being allergic to coldness." It often develops in young women in their teens and early adulthood. Primary Raynaud's is thought to be at least partly hereditary, although specific genes have not yet been identified.
Smoking increases frequency and intensity of attacks, and there is a hormonal component. Caffeine also worsens the attacks. Sufferers are more likely to have migraine and angina than controls.
Secondary Raynaud's (syndrome)
Raynaud's syndrome, or "Secondary Raynaud's," occurs secondary to a wide variety of other conditions. Secondary Raynaud's has a number of associations:
Erythromelalgia (the opposite of Raynaud's, with hot and warm extremities) often co-exists in patients with Raynaud's
It is important to realize that Raynaud's can herald these diseases by periods of more than twenty years in some cases, making it effectively their first presenting symptom. This may be the case in the CREST syndrome, of which Raynaud's is a part.
Patients with Secondary Raynaud's can also have symptoms related to their underlying diseases. Raynaud's phenomenon is the initial symptom that presents for 70% of patients with scleroderma, a skin and joint disease.
When Raynaud's phenomenon is limited to one hand or one foot, it is referred to as Unilateral Raynaud's. This is an uncommon form, and it is always secondary to local or regional vascular disease. It commonly progresses within several years to affect other limbs as the vascular disease progresses.
A careful medical history will often reveal whether the condition is primary or secondary. Once this has been established, an examination is largely to identify or exclude possible secondary causes.
Digital artery pressure: pressures are measured in the arteries of the fingers before and after the hands have been cooled. A decrease of at least 15 mmHg is diagnostic (positive).
Nail fold vasculature: this can be examined under the microscope.
Raynaud's syndrome (secondary Raynaud's) is managed primarily by treating the underlying cause and, as with Raynaud's disease (primary Raynaud's), avoiding triggers, such as cold, keeping a warm core body temperature and avoiding smoking (including passive smoking) and sympathomimetic drugs.
The prostaglandiniloprost is used to manage critical ischemia and pulmonary hypertension in RP, and the endothelin receptor agonist bosentan is used to manage severe pulmonary hypotension and prevent finger ulcers in SSc.
A more recent treatment for severe Raynaud's is the use of Botox. The 2009 article studied 19 patients ranging in age from 15 to 72 years with severe Raynaud's phenomenon of which 16 patients (84%) reported pain reduction at rest. 13 patients reported immediate pain relief, 3 more had gradual pain reduction over 1–2 months. All 13 patients with chronic finger ulcers healed within 60 days. Only 21% of the patients required repeated injections. A 2007 article describes similar improvement in a series of 11 patients. All patients had significant relief of pain.
^Anderson ME, Moore TL, Lunt M, Herrick AL (March 2007). "The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon". Rheumatology46 (3): 533–8. doi:10.1093/rheumatology/kel330. PMID17018538.Cite uses deprecated parameters (help)
^Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005). Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. p. 542. ISBN0-7216-0187-1.
^Holmen OL, Backe B (2009). "An underdiagnosed cause of nipple pain presented on a camera phone". BMJ339: b2553. doi:10.1136/bmj.b2553.
^Anderson JE, Held N, Wright K (April 2004). "Raynaud's phenomenon of the nipple: a treatable cause of painful breastfeeding". Pediatrics113 (4): e360–4. doi:10.1542/peds.113.4.e360. PMID15060268.Cite uses deprecated parameters (help)
^Goldman, William, Ryan Seltzer, and Peter Reuman. "Association between treatment with central nervous system stimulants and Raynaud's syndrome in children: A retrospective case–control study of rheumatology patients." Arthritis & Rheumatism 58.2 (2008): 563-566.
^Priollet P (October 1998). "[Raynaud's phenomena: diagnostic and treatment study]". La Revue du praticien (in French) 48 (15): 1659–64. PMID9814067.Cite uses deprecated parameters (help)
^ abcdefghMikuls, Ted R; Canella, Amy C; Moore, Gerald F; Erickson, Alan R; Thiele, Geoffery M; O'Dell, James R (2013). "Connective Tissue Diseases". Rheumatology. London: Manson Publishing. p. 117. ISBN9781840761733.
^Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (April 1981). "Nifedipine and Raynaud's phenomenon". Annals of Internal Medicine94 (4 pt 1): 546. PMID7212523.Cite uses deprecated parameters (help)
^Kahan A, Weber S, Amor B, Saporta L, Hodara M, Degeorges M (April 1982). "[Controlled study of nifedipine in the treatment of Raynaud's phenomenon]". Revue Du Rhumatisme et Des Maladies Ostéo-articulaires (in French) 49 (5): 337–43. PMID6285445.Cite uses deprecated parameters (help)
^Smith CR, Rodeheffer RJ (January 1985). "Raynaud's phenomenon: pathophysiologic features and treatment with calcium-channel blockers". The American Journal of Cardiology55 (3): 154B–157B. doi:10.1016/0002-9149(85)90625-3. PMID3881908.Cite uses deprecated parameters (help)
^Pancera P, Sansone S, Secchi S, Covi G, Lechi A (November 1997). "The effects of thromboxane A2 inhibition (picotamide) and angiotensin II receptor blockade (losartan) in primary Raynaud's phenomenon". Journal of Internal Medicine242 (5): 373–6. doi:10.1046/j.1365-2796.1997.00219.x. PMID9408065.Cite uses deprecated parameters (help)
^Dziadzio M, Denton CP, Smith R et al. (December 1999). "Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial". Arthritis and Rheumatism (Elsevier Saunergic blockers such as prazosin can be used to control Raynaud's vasospasms under supervision of a health care provider) 42 (12): 2646–55. doi:10.1002/1529-0131(199912)42:12-2646:AID-ANR21-3.0.CO;2-T. PMID10616013.Cite uses deprecated parameters (help)
^Wang WH, Lai CS, Chang KP et al. (October 2006). "Peripheral sympathectomy for Raynaud's phenomenon: a salvage procedure". The Kaohsiung Journal of Medical Sciences22 (10): 491–9. doi:10.1016/S1607-551X(09)70343-2. PMID17098681.Cite uses deprecated parameters (help)
Bakst R, Merola JF, Franks AG, Sanchez M (October 2008). "Raynaud's phenomenon: pathogenesis and management". Journal of the American Academy of Dermatology59 (4): 633–53. doi:10.1016/j.jaad.2008.06.004. PMID18656283.Cite uses deprecated parameters (help)